Cell therapy · developed by Lisata Therapeutics
AMR-001 (also coded NBS10) is a cell preparation of CD34+ cells given by intracoronary infusion. It is studied in ST segment elevation myocardial infarction.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01495364 | Phase 2 | ST Segment Elevation Myocardial Infarction | Completed | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ST Segment Elevation Myocardial Infarction
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →